There are very few companies that are currently carrying out research into new antibiotics. Much of this is due to the fact that this market wasn't as valuable in comparison to other diseases. As it stands now, there are many treatments available. However, drug development decisions must often take place several decades in advance. Additionally, the risk of new drug resistant bacteria is only beginning to grow as the scope of the problem was only realized in the past few years.
One company looking to address this growing issue is an early development company named Enanta Pharmaceuticals, Inc. (ENTA). Enanta is an biotechnology company focused on the research and development of small molecule drugs. The company's primary...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|